Early Diagnostics is revolutionizing Alzheimer's Disease diagnostics.

About Us

Early Alzheimer's Diagnostics (EAD) is a biomedical company focused on advancing the early detection of Alzheimer’s disease. We develop non-invasive diagnostic tools using vibrational spectroscopy and AI to analyze saliva and blood samples. Our goal is to deliver accurate, accessible, and scalable solutions that enable early intervention and improve patient outcomes. By combining cutting-edge optical science with advanced data analytics, EAD is setting a new standard for diagnostics in neurodegenerative disease care.

Our Mission

See It Before It Starts

Pioneering non-invasive diagnostics for Alzheimer’s through spectral science and AI.

Founded on Science, Backed by Institutions

EAD was established with foundational support from the University at Albany and the SUNY Research Foundation, enabling our scientific vision to take root. Our work is further empowered by two prestigious Phase I STTR grants—one from the National Science Foundation (NSF) for saliva-based diagnostics, and one from the National Institutes of Health (NIH) for blood-based testing. These grants validate our mission and help bring cutting-edge, non-invasive Alzheimer's diagnostics closer to reality.

patents and publications

Patents:

Our diagnostic platform is backed by issued and international patents that protect our core scientific methods:

U.S. Patent No. 9,891,108
Spectroscopic method for Alzheimer’s diagnosis using blood serum or plasma.
International Patent (WO2014055683A1)
Covers global applications and enhanced methods using silver nanoparticles.

Publications:

Ryzhikova, E., Kazakov, O., Halamkova, L., Celmins, D., Malone, P., Molho, E., Zimmerman, E.A. and Lednev, I.K. (2015), Raman spectroscopy of blood serum for Alzheimer's disease diagnostics: specificity relative to other types of dementia. J. Biophoton, 8: 58-596. https://doi.org/10.1002/jbio.201400060
Ralbovsky, N. M., Egorov, V., & Lednev, I. K. (2019).
Screening for Alzheimer's Disease Using Saliva: A New Approach Based on Machine Learning and Raman Hyperspectroscopy.Journal of Alzheimer’s Disease, 71(4), 1351–1359.
https://doi.org/10.3233/JAD-190682
Ralbovsky, N. M., & Lednev, I. K. (2018).
Raman hyperspectroscopy shows promise for diagnosis of Alzheimer's.Biophotonics International, 25(5), 38–41.

EAD in Spotlight

Amid new FDA-approved drugs, U-Albany research offers early Alzheimer's detection. NewsChannel 6, WRGB, by Lara Bryn, August 28 th , 2024.

https://cbs6albany.com/news/wellness-wakeup/amid-new-fda-approved-drugs-u-albany-research-offers-early-alzheimers-detection

Press release by Congressman Tonko’s office. $1.8 Million+ Awarded to Support Capital Region Health Programs. $306,974 for Early Alzheimer’s Diagnostics LLC to support research onearly screening for Alzheimer’s Disease based on blood spectroscopy (September 30, 2022).

https://tonko.house.gov/news/documentsingle.aspx?DocumentID=3716

Glenmont-based Alzheimer’s research facility gets $275k grant. NewsChannel 13 – WNYT. December 2, 2022. Congressman Paul Tonko announced Friday night early Alzheimer’s Diagnostics LLC of Glenmont has been awarded a national science foundation grant totaling nearly $275,000 for a project.

https://wnyt.com/top-stories/glenmont-based-alzheimers-research-facilitygets-275k-grant/

UAlbany test could detect Alzheimer's disease in seconds. Times Union, December 22, 2022.

https://www.timesunion.com/news/article/UAlbany-test-could-detect-Alzheimer-s-disease-in-

17664643.php